Autophagy-targeted therapy to modulate age-related diseases: Success, pitfalls, and new directions
Authors:
- Waleska Kerllen MartinsWMWaleska Kerllen Martins
- Maryana Do Nascimento da SilvaMSMaryana Do Nascimento da Silva
- Kiran PandeyKPKiran Pandey
- Ikuko MaejimaIMIkuko Maejima
- Ercília RamalhoERErcília Ramalho
- Vania Claudia OlivonVOVania Claudia Olivon
- Susana Nogueira DinizSDSusana Nogueira Diniz
- Daniel GrassoDGDaniel Grasso
Open Access
- 1 June 2021
- journal article
- review article
- Published by Elsevier in Current Research in Pharmacology and Drug Discovery
- Vol. 2, 100033
Abstract
No abstract availableKeywords
Funding Information
- FAPESP
- CAPES
This publication has 304 references indexed in Scilit:
- Rapamycin Attenuates the Progression of Tau Pathology in P301S Tau Transgenic MicePLOS ONE, 2013
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Lithium protects against oxidative stress‐mediated cell death in α‐synuclein‐overexpressing in vitro and in vivo models of Parkinson's diseaseJournal of Neuroscience Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Acetylation Targets Mutant Huntingtin to Autophagosomes for DegradationCell, 2009
- Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinasesNature Chemical Biology, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse modelNeuroscience, 2008
- Suppression of basal autophagy in neural cells causes neurodegenerative disease in miceNature, 2006
- Loss of autophagy in the central nervous system causes neurodegeneration in miceNature, 2006